Previous 10 | Next 10 |
home / stock / mpsyf / mpsyf news
MorphoSys AG (MPSYF) Q1 2020 Earnings Conference Call May 7, 2020 8:00 AM ET Company Participants Julia Neugebauer - Director of IR Jean Kress - Chairman of Management Board, MD & CEO Jens Holstein - CFO & Member of the Management Board Malte Peters - Chief Research &a...
The following slide deck was published by MorphoSys AG in conjunction with their 2020 Q1 earnings Read more ...
MorphoSys AG ( OTCPK:MPSYF ): Q1 GAAP EPS of €6.11. More news on: MorphoSys AG, MorphoSys AG ADR, Earnings news and commentary, Healthcare stocks news, Read more ...
Source : ClearBridge Investments Editor's Note : The summary bullets for this article were chosen by Read more ...
MorphoSys AG (MPSYF) Q4 2019 Earnings Conference Call March 19, 2020 9:00 a.m. ET Company Participants Julia Neugebauer - Director of Corporate Communications and Investor Relations Jean-Paul Kress - Chief Executive Officer Jens Holstein - Chief Financial Officer Malte Peters -...
The following slide deck was published by MorphoSys AG in conjunction with their 2019 Q4 earnings Read more ...
Introduction Now that we are in the back half of Q1, I have run out of time to do a full article on every biotech I own, have sold out of, or in other ways have discussed in the past two or so years on Seeking Alpha . So, I would like to provide commentary on several of these stocks, and al...
The core franchises of Vertex Pharmaceuticals (NASDAQ: VRTX) and Incyte (NASDAQ: INCY) continue to generate hefty sales, enabling the companies to invest heavily in exciting research and development programs. While Vertex's $63 billion valuation towers over Incyte's $17 billion market ca...
Morphosys Ag (MPSYF) Q3 2019 Results Earnings Conference Call October 30, 2019, 09:00 AM ET Company Participants Sarah Fakih - Vice President/Head of Corporate Communications & Investor Relations Jean-Paul Kress - Chief Executive Officer Jens Holstein - Chief Financial Office...
The following slide deck was published by MorphoSys AG in conjunction with their 2019 Q3 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG. Novartis BidCo Germany ...
Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 24, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new efficacy and safety data from the Phase 3 MANIFEST-2 trial of pel...
Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billion Shareholders benefit from attractive premium of 94% and 142% on the volume-weighted average price during the last month and three months before January 25, 2024, respectively Acce...